Just a thread bump with more information about CJC-1295; it’s worth the time invested while reading…I’ve been saying for sometime now that peptides are the way to go… For GHRP-6 it’s not for the faint-hearted, if you struggle with BS stability I would not suggest it although a lot of peptides may give a “false sense” of going hypo (LBG), it mainly comes with the territory of GHRP-2/6…Although it’s primarily a false sense it can feel and almost demonstrate just as equal or if not more server than a real instances of going hypo by ones own diet/exercise and or genetics and so on…Having carbs/food on hand can easily mitigate these sides for those that are sensitive, furthermore it can be capitalized on and taken advantage of for those that have a tendency to not have the urge or desire to eat, this onset may provide the ideal platform for having the need or desire to want to consume food, almost instantaneously for some…
The combo of the both have made rest and recovery a beautiful thing in respect to feeling sleepy and wanting to shut my eyes almost anywhere at any given time, not to the point where it hinders my daily life but if I wish to nap, I can, and I will wherever I wish and even a small nap at 10-20 mins I wake up feeling as if I was out for hrs, groggy, but rested and ready to pounce!
Scientific research CJC-1295
In the experiment of Ionescu M. et al. , men aged 20-40 years were given a single dose of CJC-1295 (60 or 90 microg / kg body weight CJC-1295), a blood sample was collected every 20 minutes. This means that for a person weighing 90 kg, 5400 mcg (5.4 mg) or 8100 mcg (8.1 mg) CJC-1295 was administered.
Results? After a single dose of CJC-1295:
- a 7.5-fold increase in baseline growth hormone was noted,
- total secretion of growth hormone increased by 46%, while the level of IGF-1 increased by 45%.
In another study, Teichman SL. Both co-workers  lasted 28 or 49 days. Healthy people aged 21-61 participated in it.
After a single injection of CJC-1295 (30 or 60 microg / kg body weight CJC-1295), there were:
- average 2-10 fold increase in plasma growth hormone for 6 days,
- in turn, mean plasma IGF-1 concentrations increased from 1.5 to 3 times for a period of 9-11 days,
- the half-life CJC-1295 is 5.8-8.1 days,
- after several injections of CJC-1295, the level of IGF-1 was increased above baseline values to 28 days.
GHRH agents interact through other mechanisms and synergistically together with GHRP, causing a much stronger GH and IGF-1 burst.
This is clearly demonstrated by numerous scientific studies, including experiment carried out by Popovic V. et al. .
One of the studies reported:
- GHRH - growth hormone releasing hormone (100 mcg, intravenously),
- GHRP-6 (90 mcg, intravenously),
- GHRH (growth hormone releasing hormone) + GHRP-6.
What was the effect on growth hormone?
- After growth hormone releasing hormone (GHRH), an increase in the amount of GH to the level of 483.7 +/- 99.2,
- After GHRP-6 up to level 1434.8 +/- 393.0,
- After GHRH (growth hormone releasing hormone) + GHRP-6 up to level 3 771,5 +/- 399.6!
This study clearly shows that growth hormone releasing peptides should not be used alone, without the administration of, for example, GHRH analogs (tesamorelin, TH9507, CJC-1295, MOD GRF 1-29, MR-356, MR-361, JI-38, MR-356 403, MR-367).
Side effects of using CJC-1295:
Unfortunately, there is no information on this subject, it can be suspected that, like tesamorelin CJC-1295, it can trigger:
- local inflammatory reactions at the injection site (erythema, pruritus, irritation, edema),
- rarely diabetes (!), the antagonistic effect of growth hormone on insulin!
- muscle aches,
- muscle stiffness,
- night sweating,
The website administrator recognizes the phenomenon of doping and the use of illicit substances in sport, and contrary to medical prescriptions, for extremely reprehensible, unfair and immoral. Any information contained in articles on doping and pharmacology can not be treated or served as instructions. The content of the articles presents only the information collected about the above topic. The use of doping carries the risk of losing health and in many cases even the loss of life. Study below: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL1, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.
Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.
The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.
The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
The study was performed at two investigational sites.
Healthy subjects, ages 21-61 yr, were studied.
CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.
MAIN OUTCOME MEASURES:
The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295.
After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. The estimated half-life of CJC-1295 was 5.8-8.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.
Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.
Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
GH-releasing peptide (GHRP-6; His-D Trp-Ala-Trp-D Phe-Lys-NH2) is a synthetic compound that releases GH in a specific and dose-related manner through mechanisms and a point of action that are mostly unknown but different from those of GHRH. In man, GHRP-6 is more efficacious than GHRH, and a striking synergistic action on GH release is observed when GHRP-6 and GHRH are administered simultaneously. Based on such a synergistic action, it has been hypothesized that GHRP-6 acts through a double mechanism by actions exerted both at the pituitary and hypothalamic levels. The aim of the present study was 2-fold: 1) to further characterize the mechanism of action and synergistic effects of GHRP-6; and 2) to study its action in patients with hypothalamopituitary disconnection. Twelve patients with different neuroendocrine pathologies leading to a state of hypothalamopituitary disconnection (functional stalk section) and 11 age- and sex-matched normal controls were studied. Each subject underwent 3 tests on separate occasions, being challenged with GHRH (100 micrograms, i.v.), GHRP-6 (90 micrograms, i.v.), or GHRH plus GHRP-6. GH was analyzed as the area under the curve (mean +/- SE, micrograms per L/120 min). In normal subjects GH secretion was 483.7 +/- 99.2 after GHRH, 1434.8 +/- 393.0 after GHRP-6, and 3771.5 +/- 399.6 after GHRH plus GHRP-6; the level of GH secreted after GHRH plus GHRP-6 treatment was significantly (P < 0.05) higher than after the arithmetic sum of GH levels after both compounds administered separately. In the group of patients with hypothalamopituitary disconnection, the level of GH secreted after GHRH was similar to that in controls (423.4 +/- 62.8); however, a complete blockade was observed after GHRP-6 (97.3 +/- 7.9), significantly (P < 0.05) lower than after GHRH as well as lower than the GHRP-6-induced GH release in control subjects (P < 0.01). After GHRH plus GHRP-6, the patients with hypothalamopituitary disconnection showed severely reduced secretion (745.3 +/- 67.6; P < 0.01 vs. controls), a value that was not significantly different from the arithmetic addition of levels produced by both compounds administered separately.(ABSTRACT TRUNCATED AT 400 WORDS).
Studies below highlighted red: Reference:
- Teichman SL1, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, and long-acting analogue of GH-releasing hormone, in healthy adults”. J Clin Endocrinol Metab. 2006 Mar; 91 (3): 799-805. Epub 2005 Dec 13. https://www.ncbi.nlm.nih.gov/pubmed/16352683
- Popovic V1, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. "Blocked growth hormone-releasing peptide (GHRP-6) -induced GH-releasing hormone in patients with hypothalamopituitary disconnection: GHRP-6 main action is exerted at the hypothalamic level ". J Clin Endocrinol Metab. 1995 Mar; 80 (3): 942-7. https://www.ncbi.nlm.nih.gov/pubmed/7883854
- Xiangyang Xia, 1 Quanwei Tao, 2 Qunchao Ma, 3, 4 Huiqiang Chen, 5 Jian’an Wang, 3, 4 and Hong Yu Growth “Hormone-Releasing Hormone and Its Analogues: Significance for MSCs-Mediated Angiogenesis” https: // www.ncbi.nlm.nih.gov/pmc/articles/PMC5059609/
- Knoop A1, Thomas A1, Fichant E2, Delahaut P2, Schänzer W1, Thevis M3,4. “Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS / MS.” https://www.ncbi.nlm.nih.gov/pubmed/26879649
- Ionescu M1, Frohman LA. “Pulsatile secretion of growth hormone (GH) persisted in continuous stimulation by CJC-1295, and long-acting GH-releasing hormone analog.” https://www.ncbi.nlm.nih.gov/pubmed/17018654 .